Does the media favor VYGR or STTK?

In the previous week, Shattuck Labs had 6 more articles in the media than Voyager Therapeutics. MarketBeat recorded 7 mentions for Shattuck Labs and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.42 beat Shattuck Labs' score of 0.51 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Shattuck Labs 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VYGR or SLN?

In the previous week, Silence Therapeutics had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Silence Therapeutics and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.42 beat Silence Therapeutics' score of 0.49 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VYGR or CTMX?

In the previous week, CytomX Therapeutics had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.42 beat CytomX Therapeutics' score of 0.34 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VYGR or SGMT?

In the previous week, Sagimet Biosciences had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 3 mentions for Sagimet Biosciences and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.42 beat Sagimet Biosciences' score of 0.52 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sagimet Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CBIO or VYGR?

In the previous week, Crescent Biopharma had 5 more articles in the media than Voyager Therapeutics. MarketBeat recorded 6 mentions for Crescent Biopharma and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.42 beat Crescent Biopharma's score of 0.48 indicating that Voyager Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Voyager Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Voyager Therapeutics (VYGR) Competitors

$1.90 -0.16 (-7.77%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$1.90 0.00 (-0.26%)

As of 10/16/2026 07:47 PM Eastern

Compare

VYGR vs. STTK, SLN, CTMX, SGMT, and CBIO

Should you buy Voyager Therapeutics stock or one of its competitors? Voyager Therapeutics's main competitors and comparable companies include Shattuck Labs (STTK), Silence Therapeutics (SLN), CytomX Therapeutics (CTMX), Sagimet Biosciences (SGMT), and Crescent Biopharma (CBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Voyager Therapeutics compare to Shattuck Labs?

Voyager Therapeutics (NASDAQ:VYGR) and Shattuck Labs (NASDAQ:STTK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Shattuck Labs has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Shattuck Labs' return on equity of -43.57% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
Shattuck Labs	N/A	-43.57%	-40.90%

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by insiders. Comparatively, 8.8% of Shattuck Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Voyager Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Voyager Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 768.42%. Shattuck Labs has a consensus price target of $13.70, suggesting a potential upside of 152.77%. Given Voyager Therapeutics' higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08

Shattuck Labs has lower revenue, but higher earnings than Voyager Therapeutics. Shattuck Labs is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	2.90	-$119.72M	-$1.80	N/A
Shattuck Labs	$1M	543.95	-$48.81M	-$0.51	N/A

In the previous week, Shattuck Labs had 6 more articles in the media than Voyager Therapeutics. MarketBeat recorded 7 mentions for Shattuck Labs and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.42 beat Shattuck Labs' score of 0.51 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Shattuck Labs	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Shattuck Labs beats Voyager Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Voyager Therapeutics compare to Silence Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Silence Therapeutics (NASDAQ:SLN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Voyager Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 768.42%. Silence Therapeutics has a consensus price target of $53.50, suggesting a potential upside of 516.36%. Given Voyager Therapeutics' higher possible upside, research analysts plainly believe Voyager Therapeutics is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Voyager Therapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

Silence Therapeutics has lower revenue, but higher earnings than Voyager Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	2.90	-$119.72M	-$1.80	N/A
Silence Therapeutics	$560K	933.26	-$88.61M	-$1.28	N/A

In the previous week, Silence Therapeutics had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Silence Therapeutics and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.42 beat Silence Therapeutics' score of 0.49 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Voyager Therapeutics has a net margin of -312.63% compared to Silence Therapeutics' net margin of -8,943.86%. Voyager Therapeutics' return on equity of -57.92% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Silence Therapeutics beats Voyager Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Voyager Therapeutics compare to CytomX Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Voyager Therapeutics has a net margin of -312.63% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

Voyager Therapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market.

Voyager Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 768.42%. CytomX Therapeutics has a consensus target price of $11.90, suggesting a potential upside of 421.93%. Given Voyager Therapeutics' higher probable upside, analysts clearly believe Voyager Therapeutics is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CytomX Therapeutics has higher revenue and earnings than Voyager Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	2.90	-$119.72M	-$1.80	N/A
CytomX Therapeutics	$76.20M	6.52	-$17.37M	-$0.50	N/A

In the previous week, CytomX Therapeutics had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.42 beat CytomX Therapeutics' score of 0.34 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CytomX Therapeutics beats Voyager Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Voyager Therapeutics compare to Sagimet Biosciences?

Voyager Therapeutics (NASDAQ:VYGR) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Voyager Therapeutics has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.46, meaning that its stock price is 246% more volatile than the broader market.

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sagimet Biosciences has lower revenue, but higher earnings than Voyager Therapeutics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	2.90	-$119.72M	-$1.80	N/A
Sagimet Biosciences	$2M	249.26	-$51.04M	-$1.28	N/A

Voyager Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 768.42%. Sagimet Biosciences has a consensus price target of $26.63, suggesting a potential upside of 232.10%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Sagimet Biosciences	2 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, Sagimet Biosciences had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 3 mentions for Sagimet Biosciences and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.42 beat Sagimet Biosciences' score of 0.52 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sagimet Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sagimet Biosciences has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Sagimet Biosciences' return on equity of -31.96% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
Sagimet Biosciences	N/A	-31.96%	-30.57%

Summary

Sagimet Biosciences beats Voyager Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Voyager Therapeutics compare to Crescent Biopharma?

Crescent Biopharma (NASDAQ:CBIO) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Crescent Biopharma had 5 more articles in the media than Voyager Therapeutics. MarketBeat recorded 6 mentions for Crescent Biopharma and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.42 beat Crescent Biopharma's score of 0.48 indicating that Voyager Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Voyager Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Crescent Biopharma has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

Crescent Biopharma has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Voyager Therapeutics' return on equity of -57.92% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
Voyager Therapeutics	-312.63%	-57.92%	-45.00%

Crescent Biopharma presently has a consensus target price of $32.40, indicating a potential upside of 173.65%. Voyager Therapeutics has a consensus target price of $16.50, indicating a potential upside of 768.42%. Given Voyager Therapeutics' higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Voyager Therapeutics has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	40.57	-$153.94M	-$6.72	N/A
Voyager Therapeutics	$40.37M	2.90	-$119.72M	-$1.80	N/A

Summary

Crescent Biopharma and Voyager Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Voyager Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VYGR vs. The Competition

Export

Metric	Voyager Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$126.93M	$3.97B	$7.44B	$12.94B
Dividend Yield	N/A	3.64%	2.50%	27.63%
P/E Ratio	N/A	9.30	198.80	19.05
Price / Sales	2.90	1,175.02	569.18	76.54
Price / Cash	N/A	122.10	76.54	51.88
Price / Book	0.54	15.94	10.29	5.85
Net Income	-$119.72M	-$22.69M	$3.50B	$380.67M
7 Day Performance	-22.45%	-8.66%	-5.38%	-5.00%
1 Month Performance	-37.50%	-15.39%	-9.56%	-7.94%
1 Year Performance	-61.62%	1.51%	0.84%	-5.63%

Voyager Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VYGR Voyager Therapeutics	2.8406 of 5 stars	$1.90 -7.8%	$16.50 +768.4%	-64.4%	$126.93M	$40.37M	N/A	141	Positive News
STTK Shattuck Labs	2.5905 of 5 stars	$6.09 +2.0%	$13.70 +125.0%	+201.1%	$599.17M	$1M	N/A	40	Short Interest Increase Gap Up
SLN Silence Therapeutics	2.47 of 5 stars	$9.65 -2.1%	$53.50 +454.4%	+31.7%	$593.66M	$560K	N/A	88	Analyst Forecast Gap Down
CTMX CytomX Therapeutics	2.2266 of 5 stars	$2.42 -5.8%	$11.90 +391.7%	-30.5%	$560M	$76.20M	N/A	69	Analyst Forecast
SGMT Sagimet Biosciences	3.0314 of 5 stars	$8.80 -1.5%	$26.63 +202.7%	+6.2%	$555.08M	$2M	N/A	16	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VYGR) was last updated on 10/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Voyager Therapeutics (VYGR) Competitors

VYGR vs. STTK, SLN, CTMX, SGMT, and CBIO

How does Voyager Therapeutics compare to Shattuck Labs?

Summary

How does Voyager Therapeutics compare to Silence Therapeutics?

Summary

How does Voyager Therapeutics compare to CytomX Therapeutics?

Summary

How does Voyager Therapeutics compare to Sagimet Biosciences?

Summary

How does Voyager Therapeutics compare to Crescent Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR vs. The Competition

Voyager Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Voyager Therapeutics (VYGR) Competitors

VYGR vs. STTK, SLN, CTMX, SGMT, and CBIO

How does Voyager Therapeutics compare to Shattuck Labs?

Is VYGR or STTK more profitable?

Do institutionals & insiders have more ownership in VYGR or STTK?

Which has more volatility & risk, VYGR or STTK?

Do analysts prefer VYGR or STTK?

Which has higher valuation & earnings, VYGR or STTK?

Does the media favor VYGR or STTK?

Summary

How does Voyager Therapeutics compare to Silence Therapeutics?

Do analysts prefer VYGR or SLN?

Which has more risk & volatility, VYGR or SLN?

Which has higher earnings & valuation, VYGR or SLN?

Does the media refer more to VYGR or SLN?

Is VYGR or SLN more profitable?

Do insiders and institutionals hold more shares of VYGR or SLN?

Summary

How does Voyager Therapeutics compare to CytomX Therapeutics?

Is VYGR or CTMX more profitable?

Which has more volatility & risk, VYGR or CTMX?

Do analysts prefer VYGR or CTMX?

Do insiders & institutionals hold more shares of VYGR or CTMX?

Which has stronger earnings and valuation, VYGR or CTMX?

Does the media prefer VYGR or CTMX?

Summary

How does Voyager Therapeutics compare to Sagimet Biosciences?

Which has more risk and volatility, VYGR or SGMT?

Do institutionals and insiders hold more shares of VYGR or SGMT?

Which has better valuation and earnings, VYGR or SGMT?

Do analysts prefer VYGR or SGMT?

Does the media prefer VYGR or SGMT?

Is VYGR or SGMT more profitable?

Summary

How does Voyager Therapeutics compare to Crescent Biopharma?

Do institutionals & insiders believe in CBIO or VYGR?

Does the media favor CBIO or VYGR?

Which has more risk and volatility, CBIO or VYGR?

Is CBIO or VYGR more profitable?

Do analysts recommend CBIO or VYGR?

Which has preferable earnings and valuation, CBIO or VYGR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR vs. The Competition

Voyager Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools